{"id":"W4281693510","doi":"10.1200/jco.2022.40.16_suppl.1018","title":"Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), <i>PIK3CA</i>-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Letrozole; Cohort; Internal medicine; Fulvestrant; Hazard ratio; Oncology; Breast cancer; Cancer; Gastroenterology; Estrogen receptor; Confidence interval; Aromatase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006728224,0.000284649,0.0004850677,0.0001760686,0.0001218589,0.0004975316,0.0002416467,0.0002977267,0.001514133],"category_scores_gemma":[0.0005170733,0.000161957,0.0006634972,0.0002751269,0.0001983676,0.0004123676,0.0002818032,0.0008379807,0.000250874],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003732889,"about_ca_system_score_gemma":0.0004305936,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005399197,"about_ca_topic_score_gemma":0.001519614,"domain_scores_codex":[0.9997867,0.00009914801,0.0000127422,0.00003697126,0.00002970056,0.00003474566],"domain_scores_gemma":[0.9995899,0.00008500649,0.0001402685,0.00002830906,0.0000185798,0.0001380134],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4656682,0.008815117,0.3811658,0.0005182351,0.00193727,0.0003128159,0.0002813764,0.002088137,0.02341718,0.0002940394,0.003508102,0.1119938],"study_design_scores_gemma":[0.06568272,0.2518263,0.6540326,0.0001318307,0.002014596,0.001806581,0.000377294,0.003579043,0.008493343,0.0005629234,0.01143829,0.00005436431],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9980743,0.0007807161,0.00008794845,0.0000671126,0.000008459464,0.00006361121,0.0004264678,0.000006860569,0.0004845249],"genre_scores_gemma":[0.997278,0.0005055744,0.0002176548,0.0001366013,0.00002396667,0.00008478207,0.001320747,0.000003487437,0.0004291393],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001514133,"threshold_uncertainty_score":0.005065322,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.031121113661463,"score_gpt":0.3935998460232075,"score_spread":0.3624787323617445,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}